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Abstract
Prolonged treatment of leukemic cells with chemotherapeutic agents frequently results in development of drug re-
sistance. Moreover, selection of drug-resistant cell populations may be associated with changes in malignant prop-
erties such as proliferation rate, invasiveness, and immunogenicity. In the present study, the sensitivity of cytarabine
(1-β-D-arabinofuranosylcytosine, araC)-resistant and parental human leukemic cell lines (T-lymphoid H9 and acute
T-lymphoblastic leukemia Molt-4) to natural killer (NK) cell–mediated killing was investigated. The results obtained
demonstrate that araC-resistant H9 andMolt-4 (H9rARAC100 andMolt-4rARAC100) cell lines are more sensitive to NK
cell–mediated lysis than their respective parental cell lines. This increased sensitivity was associated with a higher
surface expression of ligands for the NK cell–activating receptor NKG2D, notably UL16 binding protein-2 (ULBP-2)
and ULBP-3 in H9rARAC100 and Molt-4rARAC100 cell lines. Blocking ULBP-2 and ULBP-3 or NKG2D with monoclonal
antibody completely abrogated NK cell lysis. Constitutive phosphorylated extracellular signal–regulated kinase (ERK)
but not pAKT was higher in araC-resistant cells than in parental cell lines. Inhibition of ERK using ERK inhibitor
PD98059 decreased both ULBP-2/ULBP-3 expression and NK cell cytotoxicity. Furthermore, overexpression of con-
stitutively active ERK in H9 parental cells resulted in increased ULBP-2/ULBP-3 expression and enhanced NK cell
lysis. These results demonstrate that increased sensitivity of araC-resistant leukemic cells to NK cell lysis is caused
by higher NKG2D ligand expression, resulting from more active ERK signaling pathway.
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Introduction
Nucleoside analogs represent a group of cytotoxic antimetabolites in
the treatment of hematological malignancies, solid tumors and viral
infections [1–4]. They mimic physiological nucleosides and share
their metabolic pathways. Cytarabine (1-β-D-arabinofuranosylcytosine,
araC), a deoxycytidine analog, is one of the most important anti-
leukemic drugs currently available for the treatment of acute myeloid
leukemia [5,6], relapsed and refractory acute lymphoblastic leukemia
[7–9], and large cell lymphoma [10]. Prolonged, in vitro and in vivo,
treatment with araC has, however, resulted in the emergence of drug
resistant cells with diminished sensitivity to the drug and ultimately
contributing to treatment failures [6,11–13].
Acquired drug resistance of leukemic cells caused by pretreatment
with cytostatic drugs influences the sensitivity of leukemic cells to-
ward cytotoxic lymphocytes [14–19]. Whereas some reports show
decreased sensitivity of drug-resistant leukemic cells to cellular cyto-
toxicity [17,18,20,21], Posovszky et al. [19] reported that chemother-
apeutic drugs including araC sensitize pre-B acute lymphoblastic
leukemia (ALL) cells for CD95- and cytotoxic T-lymphocyte–mediated
apoptosis. Recent studies have shown that natural killer (NK) cells
display cytolytic activities by engagement of receptors involved in
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NK cell activation and inhibition [22]. Although NK cells can kill
target cells spontaneously without prior stimulation, a delicate bal-
ance between signaling through inhibitory [killer immunoglobulin-
like receptors (KIR), CD94-NK group 2, member A (NKG2A)]
and activating receptors [natural cytotoxic receptors (NCRs-NKp30,
NKp44, and NKp46), NK group 2, member D (NKG2D), and
DNAX accessory molecule-1 (DNAM-1)] tightly regulates their acti-
vation [22].
The relevance of the NKG2D/NKG2D ligand system for the im-
mune surveillance in patient leukemia cells was previously described
[23]. Salih et al. [23] reported that leukemia cells from patients var-
iously express major histocompatibility complex class I (MHC-I)–
related chain A/B (MICA/B) and UL16 binding protein (ULBP).
They also showed that patient leukemia cells were lysed by NK cells
in an NKG2D-dependent fashion. The NKG2D receptor is consti-
tutively expressed on the cell surface of human NK cells [24], γδT
cells, and CD8+ αβT cells [25]. The proposed role of the NKG2D
receptor in innate and adaptive immune responses to cellular and tis-
sue stress is based on the ability of the receptor to stimulate cytotoxic
effects of NK cells and T cells against virally infected cells and tumor
cells in vitro and in vivo [26]. Specifically, NKG2D receptor ac-
tivation can induce target cell lysis and trigger the production of
cytokines [27,28] and chemokines [27,29,30], as well as perforin
and granzyme involved in cellular lysis [31]. DNAX accessory
molecule-1, a coactivating receptor of NK cells, is another surface
molecule that has been shown to participate in NK cell activation
[32,33]. DNAX accessory molecule-1 is known to be involved not
only in NK cell activation but also in cell-cell adhesion [34]. It
has been shown that the susceptibility of tumor cells to NK cell–
mediated lysis is dependent on the expression level of polio virus re-
ceptor (PVR) specifically recognized by DNAM-1 [32,33,35,36].
In this study, the expression of ligands of NK cell–activating and
–inhibitory receptors on parental andH9rARAC100 andMolt-4rARAC100
cell lines and their function in NK cell–mediated cytolytic activity
were investigated. The possible mechanism involved in the expression
pattern of the ligands was also studied.
Materials and Methods
Cell Lines
The human T cell lymphoma H9 and acute T lymphoblastic leuke-
mia Molt-4 cell lines were obtained from the American Type Culture
Collection (Rockville, MD; ATCC Nos. HTB-176 and CRL 1582,
respectively). The araC-resistant H9 and Molt-4 cell sublines were es-
tablished by exposing parental cells to increasing concentrations of
the drug. The resistant sublines were grown for more than 6 months
in Iscove’s modified Dulbecco’s medium (IMDM) supplemented
with 10% fetal calf serum (FCS) and containing 100 μM araC (des-
ignated H9rARAC100 and Molt-4rARAC100, respectively). All experi-
ments were performed using araC-resistant cells subcultured at 5-day
intervals without further addition of drug. All culture media and
media supplements were purchased from Seromed (Berlin, Germany).
The cells were propagated in IMDM supplemented with 10% FCS,
100 IU/ml penicillin, and 100 mg/ml streptomycin at 37°C in a
humidified 5% CO2 incubator. The NK cell sensitive erythroleu-
kemic cell line K562 (ATCC No. CCL-243) was maintained in
IMDM supplemented with 20% FCS and used as control for NK
cell cytotoxicity.
MTT Assay
Cell viability was investigated using the modified 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl-tetrazolium-bromide (MTT) assay as previ-
ously described [37]. Briefly, cells were grown in 96-well plates with
and without addition of drugs. After the incubation period, MTT
reagent was added for 4 hours. Thereafter, 100 μl of sodium dodecyl
sulfate (SDS) solution (20% SDS in a 1:1 dimethyformamide/H2O
solution) was added for a further 4 hours. Plates were read on a multi-
well scanning spectrophotometer (Tecan, Crailsheim, Germany) at a
wavelength of 560 nm and a reference wavelength of 620 nm. Cell
viability was determined as the relative reduction of the amount of
MTT reduced by cells to its purple formazan derivative, which corre-
lates with the amount of viable cells in relation to cell control.
Polyclonal NK Cells Preparation
Human peripheral blood mononuclear cells were isolated from the
blood of healthy volunteers by Ficoll-Hypaque centrifugation. Freshly
isolated peripheral blood mononuclear cells were incubated for 2 hours
at 37°C to allow adherence of monocytes to the bottom of the culture
flasks. The cell suspension was collected and NK cells were separated
according to manufacturer’s protocol using the MACS NK cell isola-
tion kit II (Miltenyi Biotec, Bergisch Gladbach, Germany). The sep-
arated NK cells were treated with 100 U/ml recombinant human
interleukin-2 (IL-2; Cell Concepts, Umkirch, Germany) for 5 days.
Flow cytometric analysis to determine the purity of NK cells showed
that more than 90% of the cells were CD56+CD3− (data not shown).
Antibodies, Reagents, and Measurement of
Cell Surface Receptors
AraC was obtained from Sigma (Deisenhofen, Germany), the ERK
inhibitor PD98059 was from Calbiochem (Darmstadt, Germany),
and purified NKG2D was from BD Pharmingen (San Diego, CA).
For quantitative analysis of the expression of PVR, MICA/B,
ULBP-1, ULBP-2, ULBP-3, and MHC-I, a one-color cytofluoro-
metric analysis (FACScan; Becton Dickinson, Heidelberg, Germany)
was carried out. Cells were stained with mouse monoclonal to PVR,
ab3142 (Abcam, Cambridge, UK), antihuman MICA/MICB mono-
clonal antibody (mAb), BAMO1 (Immatics, Tuebingen, Germany),
ULBP1-3 (R&D Systems, Wiesbaden, Germany) followed by phyco-
erythrin (PE)-conjugated goat antimouse IgG second reagent (R&D
Systems). Fluorescein isothiocyanate–conjugated mouse monoclonal
antihuman HLA class I (Biosource, CA) was used for MHC-I expres-
sion measurements.
Natural Killer Cytotoxicity Assay
Natural killer cells were tested for cytolytic activity against indi-
cated target cells using the “aCella-Tox” kit (Cell Technology, Moun-
tain View, CA) as previously described [36]. Briefly, target cells were
plated in triplicate (5000 cells per well) in a 96-well white plate
(Greiner Bio-One, Frickenhausen, Germany). Effector cells (NK
cells) at indicated effector to target (E/T) ratios were added. Sponta-
neous effector and target cell death was accomplished by including
control wells of effector and target cells at numbers corresponding
to those of their various E/T ratios. To determine maximum release
[total glyceralehyde-3-phosphate dehydrogenase (G3PDH) released],
10 μl of lytic reagent (0.5% NP-40/100 μl sample) was added to the
target cells positive control 10 minutes to end of assay incubation. At
the end of 4 hours of incubation, 100 μl of 2× enzyme assay reagent
was added to each well. Fifty microliters of 1× detection reagent was
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immediately added to each well. The plate was read at once in a lumi-
nometer (Glomax; Promega, Mannheim, Germany). For the mAb-
mediated neutralization experiments, NK cells were first incubated
for 1 hour with 50% human serum (to prevent binding of the mAbs
to the various Fc receptors expressed on the surface of human NK
cells) and washed. Leukemic and NK cells were then incubated ini-
tially at room temperature for 20 minutes with 20-μg/ml indicated
mAb. End concentration of mAb for the 4-hour assay was 4 μg/ml.
Isotype control IgG (Becton Dickinson, San Jose, CA) was used as
negative control. Iscove’s modified Dulbecco’s medium supplemented
with 1% heat-inactivated FCS was used as assay medium. The percent
cytotoxicity was calculated as follows: [(experimental G3PDH release −
spontaneous G3PDH release from effector cells alone − spontaneous
G3PDH release from target cells alone) / (maximum G3PDH release
from target cells − spontaneous G3PDH release from target cells)] ×
100. The spontaneous target cell release was always <20% of maxi-
mum release.
Real-time Polymerase Chain Reaction
Total RNA was isolated using TRI reagent (Sigma-Aldrich, Seelze,
Germany) according to the manufacturer’s protocol. Reverse transcrip-
tion was carried out with reagents from Applied Biosystems (Foster
City, CA) according to the manufacturer’s instructions. cDNA was
quantified by quantitative real-time polymerase chain reaction
(PCR) with the ABI PRISM 7900HT. All reactions were performed
using SYBR Green assays according to a standard thermal profile: de-
naturation at 95°C for 15 seconds, annealing/extension at 60°C for
60 seconds with 40 repeats. Primers for ULBP-2 are as follows: for-
ward 5′-CCC TGG GGA AGA AAC TAA ATG TC-3′; reverse 5′-
ACT GAA CTG CCA AGATCC ACTGCT-3′. Primers for ULBP-3
are as follows: forward 5′-AGA TGC CTG GGG AAA ACA ACT G-
3′; reverse 5′-GTA TCC ATC GGC TTC ACA CTC ACA-3′. Pri-
mers for β-actin are as follows: forward 5′-CGC GAG AAG ATG
ACC CAG AT-3′; reverse 5′-CAG AGG CGT ACA GGG ATA
GCA-3′. All the samples were performed at least in duplicates. Thresh-
old levels and baseline were optimized. Relative quantification was de-
termined with the SDS2.1 software (Applied Biosystems) provided
with the ABI PRISM 7900HT (ΔΔCt method). Normalization was
obtained by using β-actin as endogenous control and the parental cell
culture as calibration sample in comparison to the araC-resistant cell
cultures. The results are presented as fold increase.
Western Blot
Western blot analysis was performed as previously described [38].
Briefly, cell lysates were subjected to SDS-PAGE before transferring
to nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany)
using the Mini-Protean II System (Bio-Rad, Munich, Germany). After
transfer, blots were blocked in Tris-buffered saline blocking buffer
containing 3% bovine serum albumin for 1 hour at room temperature
to saturate the nonspecific protein-binding sites on the nitrocellulose
membrane. The following primary rabbit polyclonal Abs were used:
ERK, anti–phospho-ERK1/2, AKT, anti–phospho-AKT (ser 473;
Cell Signaling, Beverly, MA). Mouse polyclonal β-actin Ab was from
Sigma-Aldrich (Munich, Germany). The blots were incubated over-
night with the primary Ab diluted in Tris-buffered saline at 4°C with
gentle agitation. After a 1-hour incubation period with peroxidase-
conjugated secondary Ab at room temperature, visualization was
performed by enhanced chemiluminescence using a commercially
available kit (Amersham, Liverpool, UK).
Inhibition of ERK Activation
Inhibition of ERK activation was performed by pretreating both
parental and araC-resistant cells for 48 hours with 20 μM PD98059.
Transfection and Plasmid
The constitutively active ERK 2 expression plasmid was kindly
provided by Professor Stefanie Dimmeler (Frankfurt, Germany).
Plasmids included (pcDNA3.1; empty vector) as a control and con-
stitutively active ERK (pcDNA3.1 ERK2). A total of 2 × 106 H9
cells were transfected with 2 μg of plasmid using Amaxa Nucleofec-
tion Technology (Cologne, Germany). Transfection efficiency was
approximately 58% as determined using green fluorescent protein,
and maximal levels of protein expression were observed between
72 and 96 hours.
Measurement of Interferon-γ Production
A total of 2 × 104 leukemic cells (H9, H9rARAC100, Molt-4,
and Molt-4rARAC100) were cocultured with 2 × 105 NK cells for
24 hours. Natural killer cells alone or leukemic cells were used as
control. Supernatants were collected and tested for production of
interferon-γ (IFN-γ). The amounts of IFN-γ were determined using
the Quantikine Human IFN-γ ELISA kit (R&D Systems) according
to the manufacturer’s protocol.
Statistics
Values presented are the mean ± SD of at least three experiments.
Comparisons between two groups were performed using Student’s
t test. P values <.05 were considered to be significant.
Results
Viability of Leukemic Cells on araC Treatment
MTT assay was performed to determine the viability of the leuke-
mic cell lines used on treatment with araC. Cytotoxic effects of araC,
expressed as concentrations inhibiting 50% of cell growth (IC50),
were decreased in araC-resistant cells when compared with parental
cells. Resistance indexes (RIs; ratio of IC50 in H9
rARAC100 and H9
cells as well as in Molt-4rARAC100 and Molt-4 cells) of araC for H9
and Molt-4 cells were 2.2 × 104 and 4.3 × 104, respectively (Table 1).
Cytotoxic Activity of NK Cells Against Leukemic Cell Lines
The cytolytic activities of IL-2–activated NK cells against parental
as well as H9rARAC100 and Molt-4rARAC100 cell lines were deter-
mined. The results show that NK cells effectively kill parental H9
and Molt-4 cell lines. Both araC-resistant cell lines showed higher
sensitivity to NK cell lysis than parental cell lines (11% and 55%
Table 1. Cytotoxic Effects of araC in Molt-4, Molt-4rARAC100, H9, and H9rARAC100 Cells.
Cells IC50 (μM)* RI
†
Without PD98059 With PD98059
Molt-4 0.029 ± 0.0018 0.024 ± 0.0016 4.3 × 104
Molt-4rARAC100 1256 ± 234 1450 ± 195
H9 0.034 ± 0.0047 0.031 ± 0.0051 2.2 × 104
H9rARAC100 756.8 ± 53.7 695.6 ± 78.9
PD98059 was added at a concentration of 20 μM.
*Results represent mean values ± SD of three different experiments.
†RI (ratio IC50 resistant, IC50 parental cell lines without PD98059).
1404 NK Cell Lysis of araC-resistant Leukemic Cells Ogbomo et al. Neoplasia Vol. 10, No. 12, 2008
at E/T 1:1 and 4:1, respectively, for H9rARAC100 vs 6% and 38% at
E/T 1:1 and 4:1, respectively, for H9; 29% and 70% at E/T 1:1 and
4:1, respectively, for Molt-4rARAC100 vs 4% and 31% at E/T 1:1
and 4:1, respectively, for Molt-4; Figure 1, A and B). To exclude
the direct effects of araC on leukemic cell sensitivity to NK cells, re-
sistant cells used for the experiment were cultured for at least three
subcultures without the drug. Similar results were obtained with the
cells cultured up to 10 passages without the drug (not shown). Nat-
ural killer cell lysis of K562 cell line was used as positive control, and
it resulted to approximately 90% lysis (E/T 4:1; not shown). The
cytolytic activities of freshly isolated NK cells against parental as well
as H9rARAC100 and Molt-4rARAC100 cell lines were also tested.
Both araC-resistant cell lines also showed higher sensitivity to NK
cell lysis than their parental counterparts. Lysis of leukemic cells
was, however, detectable only at higher E/T ratios (32% and 62% at
E/T 10:1 and 20:1, respectively, for H9rARAC100 vs 20% and 45% at
E/T 10:1 and 20:1, respectively, for H9; 47% and 58% at E/T 10:1
and 20:1, respectively, for Molt-4rARAC100 vs 30% and 41% at E/T
10:1 and 20:1, respectively, for Molt-4; Figure 1, C and D). The pro-
duction of IFN-γ by NK cells was also measured upon coculture of
NK cells with parental as well as H9rARAC100 and Molt-4rARAC100
cell lines. Cocultures of NK cells with parental H9 and Molt-4 cells
resulted in 320 ± 25 and 57 ± 12 pg/ml IFN-γ, respectively, for NK/
H9 and NK/Molt-4 cocultures. The IFN-γ production was increased
2.25- and 1.7-fold, respectively, in NK/H9rARAC100 and NK/Molt-
4rARAC100 cocultures. IL-2–activated NK cells were used for further
cytotoxic experiments because low E/T ratios are required.
Expression of NK Cell–Activating and –Inhibitory Ligands on
Surface of Leukemic Cells
The expression pattern of ligands for theNKcell–activating/inhibitory
receptor on the surface of both parental and araC-resistant cell lines
was investigated to show whether it correlates with the lysis of leu-
kemic cells by NK cells. Results obtained show that increased NK
cell lysis of leukemic cells was associated with a corresponding in-
crease in the cell surface expression of ULBP-2, ULBP-3, and PVR
in H9rARAC100 (relative fluorescent units: 380 vs 217 for ULBP-2,
122 vs 50 for ULBP-3, and 43 vs 27 for PVR; Figure 2A). In Molt-
4rARAC100 cells, ULBP-2 and ULBP-3 cell surface expression were
highly increased, whereas no change was observed for PVR (relative
fluorescent units: 82 vs 29 for ULBP-2, 31 vs 6 for ULBP-3, and 10 vs
8 for PVR; Figure 2A). There was no significant change in MHC-I
expression level in both parental and araC-resistant cell lines. Both pa-
rental and araC-resistant leukemic cell lines did not express MICA/B
or ULBP-1 except for Molt-4, which showed minimal expression of
ULBP-1 (not shown). The mRNA expression of araC-resistant and
parental cell lines used for this study was also evaluated using real-time
PCR. As shown in Figure 2B, an increased ULBP-2 and ULBP-3
mRNA expression was observed in araC-resistant cell lines (approxi-
mately two-fold ULBP-2, six-fold ULBP-3 increase for H9rARAC100
and six-fold ULBP-2, two-fold ULBP-3 for Molt-4rARAC100) in
comparison to their respective parental cell lines. This indicates that
araC modifies the NK cell–activating receptor ligand expression at
the transcriptional level. The effect of this modification seems to be
maintained because several passaging of leukemic cells continued to
display this effect (not shown).
NK Cell Recognition of Leukemic Cell Lines Through NKG2D
In an attempt to understand a possible mechanism of the increased
NK cell lysis of resistant leukemic cells as well as the functionality of
NKG2D ligands, mAb masking experiments were performed. As
shown in Figure 3, blocking PVR on H9 and H9rARAC100 cells
did not show significant decrease in NK cell lysis (36% vs 33%
and 58% vs 50%, respectively for H9 and H9rARAC100). However,
Figure 1. Natural killer cell cytotoxicity of parental and araC-resistant leukemic cells. Killing of H9 and H9rARAC100 (H9 araC) as well as
Molt-4 and Molt-4rARAC100 (Molt-4 araC) cell lines was assessed by G3PDH release using acella-Tox kit. Five thousand target cells were
coincubated with IL-2–activated NK cells (A and B) or freshly isolated NK cells (C and D) at the indicated E/T ratios for 4 hours at 37°C.
The results are mean ± SD of three independent experiments. *P < .05 compared with parental control.
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blocking ULBP-2 or ULBP-3 alone showed a strong inhibition of
NK cell lysis (36% vs 3% ULBP-2 and 4% ULBP-3, 58% vs 4%
ULBP-2 and 15% ULBP-3, respectively, for H9 and H9rARAC100).
In both H9 and H9rARAC100 cell lines, the expression level of
ULBP-2 and ULBP-3 was approximately eight- and two-fold higher,
respectively, than that of PVR. Combined blocking of ULBP-2 and
ULBP-3 on H9rARAC100 cells resulted in total abrogation of NK
cell lysis. A 100% inhibition of NK cell lysis was also observed on
blocking NKG2D on NK cells (Figure 3). Similar results were ob-
tained using Molt-4 and Molt-4rARAC100 cell lines (not shown). The
results suggest that NK cell activation through NKG2D receptor–
ligand binding is the possible mechanism involved in the increased
lysis of H9rARAC100 and Molt-4rARAC100 cell lines.
Possible Mechanism of Increased Ligand Expression in
araC-Resistant Leukemic Cells
Extracellular signal–regulated kinase and AKTmay influence sen-
sitivity of leukemic cells to araC [39–41]. Moreover, both ERK and
Figure 2. Expression of ligands for NK cell receptors in leukemic cells. (A) Flow cytometric analysis for the expression of ligands in H9
and H9rARAC100 cells and Molt-4 and Molt-4rARAC100 cells. Black line shows isotype control staining, and black-filled histogram shows
indicated antibody staining for both H9rARAC100 and Molt-4rARAC100 cell lines. Gray-filled histograms shows isotype control staining,
and gray line shows indicated antibody staining for both H9 and Molt-4 cell lines. One representative of at least three separate experi-
ments is shown. (B) Real-time reverse transcription–PCR for the mRNA expression levels of ULBP-2 and ULBP-3 transcripts. Data are
expressed as mRNA fold increase in H9rARAC100 and Molt-4rARAC100 cells relative to parental H9 and Molt-4 cells. Histograms are
representative of three different experiments. Each experiment was run in duplicate; error bars indicate ±SD. *P < .05 compared with
parental control.
Figure 3. Natural killer cells recognize leukemic cells through
NKG2D receptor. Five thousand H9 and H9rARAC100 cells were
coincubated with IL-2–activated NK cells at an E/T ratio of 4:1 for
4 hours at 37°C either in the absence or in the presence of mAb.
IgG isotype control was used as negative control. The results are
mean ± SD of three independent experiments. *P < .05 compared
with cells not blocked with mAb.
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AKT were shown to be involved in the regulation of expression of
NKG2D ligands [42,43]. For these reasons, both ERK and AKT sig-
naling pathways were studied for their constitutive activation status
in both parental and araC-resistant cells. Western blot analysis using
parental H9 as well as H9rARAC100 cells showed a stronger consti-
tutive phosphorylated ERK but not AKT in H9rARAC100 cells (Fig-
ure 4A). To verify the role of ERK signaling pathway in NKG2D
ligand expression, flow cytometric analysis and cytotoxicity assay
were performed on ERK inhibition of parental H9 and H9rARAC100
cells using 20 μM PD98059. Treatment of both parental and araC-
resistant leukemic cell lines with PD98059 shows only minimal
effect on cell viability (Table 1). It, however, suppressed their ERK
activation status, decreased ULBP-2 (relative expression from 182 to
152 and 266 to 102 for H9 and H9rARAC100, respectively) and
ULBP-3 (relative expression from 24 to 14 and 60 to 49 for H9
and H9rARAC100, respectively) surface expression and impaired
NK cell lysis (from 50% to 39% and 68% to 43% for H9 and
H9rARAC100, respectively; Figure 4, B–D). These results were fur-
ther confirmed by transfecting parental H9 cells with constitutively
active ERK (Figure 5). Transfection of parental H9 cells with consti-
tutively active ERK resulted to 1.9- and 2.1-fold higher ULBP-2 and
ULBP-3 ligand expression, respectively, when compared with paren-
tal H9 cells (Figure 5B). It also enhanced NK cell lysis by 1.52-fold
compared with parental H9 cells (Figure 5C ). Furthermore, blocking
ULBP-2 and ULBP-3 with mAb inhibited NK cell lysis (Figure 5D).
Taken together, these results demonstrate that increased sensitivity of
araC-resistant leukemic cells to NK cell lysis is caused by higher
NKG2D ligand expression, resulting from more active ERK but
not AKT signaling pathway.
Discussion
Numerous experimental studies demonstrated that drug exposure
may induce not only resistance but also change other properties of
tumor cells which may be related to tumor growth, invasiveness,
and immunogenicity [36,44–47]. The present study shows that re-
sistance of T-cell leukemia cell lines to araC is associated with in-
creased sensitivity to NK cell–mediated lysis. These effects were
not caused by direct activity of araC on cell metabolism but rather
by selection of cell population with altered susceptibility to NK cells
because the resistant cells cultured for at least three passages in a me-
dium without the drug were lysed by NK cells to a greater extent
than the parental cell population.
Selection of chemotherapy-resistant tumor cells may be associated
with increased immunogenicity. Although increased immunogenicity
of malignant cells resistant to chemotherapeutic agents has been re-
ported previously [19,36], mechanisms responsible for such effects
Figure 4. Mechanism of increased ligand expression in araC-resistant cells. (A) The same amount of cell extracts prepared from the
same passage of H9 and H9rARAC100 cell cultures was used for Western blot analyses. Constitutive AKT and ERK activation was as-
sessed using antibodies that recognize AKT phosphorylated at ser-473 and ERK1/2 phosphorylated at Thr202/Tyr204. (B) Western blot
analysis of H9 and H9rARAC100 cells after specific inhibition of ERK activation using PD98059. Data are representative of at least three
experiments. (C) Flow cytometric analysis for ULBP-2 and ULBP-3 expression in H9 and H9rARAC100 cells after a 48-hour treatment with
PD98059 (PD). Results are representative of three different experiments. Error bars indicate ±SD, *P < .05 compared with parental H9
cell line. (D) IL-2–activated NK cell cytotoxicty of H9 and H9rARAC100 cells after a 48-hour treatment with PD98059. Results are repre-
sentative of three different experiments. Error bars indicate ±SD, *P < .05 compared with H9rARAC100 cell line without PD. #P < .05
compared with parental H9 cell line without PD.
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remain poorly understood. This work focuses on the role of specific
ligands for NK cell–activating receptors in the susceptibility of paren-
tal and araC-resistant leukemic cells to NK cell lysis. H9 and Molt-4
cells express NKG2D ligands (particularly ULBP-2 and ULBP-3) in
addition to PVR (ligand for NK cell–coactivating receptor DNAM-1),
whereas they do not express other NKG2D ligands including MICA
and MICB. This is in concordance with the hypothesis by Pende
et al. [48] stating that most T-cell leukemia cell lines are character-
ized by a MICA-ULBP+ phenotype. The results, with particular ref-
erence to the blocking experiments, show that increased expression
of ULBP-2 and ULBP-3 rendered araC-resistant leukemic cell lines
to become more sensitive to NK cell lysis. Blocking PVR with mAb
could not inhibit NK cell lysis, suggesting that DNAM-1 is not
involved in NK cell lysis of H9 and Molt-4 cell lines. The increased
NK cell lysis of H9rARAC100 and Molt-4rARAC100 cells could
still be observed despite expression of MHC-I molecules on their
surface. These findings suggest that ULBP-NKG2D interaction is
a major determinant for susceptibility of H9 and Molt-4 cell lines
to NK cell lysis.
The expression of NK cell–activating receptor ligands, especially
NKG2D ligands, has been shown to be associated with malig-
nant transformation, whereas they are generally only transiently ex-
pressed on healthy tissues [49]. Recent experiments demonstrated
that NKG2D/NKG2D ligand system stimulates immune surveil-
lance of tumors [50–52]. The capacity of the NKG2D ligand–
expressing tumor cell lines to stimulate tumor immunity in vivo
was critically dependent on the expression levels of NKG2D ligands
on the tumor cell surface. In previous studies, NKG2D ligand sur-
face expression led to increased susceptibility of malignant or virus-
infected cells to NK cell– or T cell–mediated lysis [27,28]. Because
NK cell activity is guided by a balance of activating and inhibitory
signals, and an enhanced NKG2D ligand expression is able to trig-
ger NK cells overcoming inhibitory signals by MHC-I molecules
[25,27], even modest changes in NKG2D ligand expression may crit-
ically influence NK cell cytotoxic potential. The significance of
NKG2D signaling in protection against infection and tumorigenesis
is highlighted by the development of mechanisms by viruses and tu-
mor cells to evade detection by this system. Independent reports by
Oppenheim et al. [53], Wiemann et al. [54], and Coudert et al. [55],
described the down-modulation and altered function of NKG2D in
immune effector cells after chronic exposure to its ligands on tumor
cells. Therefore, in addition to being involved in increased protection
against tumor progression, enhanced expression of NKG2D ligands
on surface of araC-resistant cells may also contribute to the evasion of
leukemic cells from NK cell reactions during chronic exposure of
NKG2D on NK cell surface to NKG2D ligands expressed on the
surface of leukemic cells.
Several mechanisms of resistance to araC, such as increased in-
activation of araC by cytidine deaminase, decreased intracellular
permeation, decreased cellular activation by deoxycytidine kinase,
increased degradation of araC nucleotides by 5′-nucleotidase, imbal-
ance of cellular deoxynucleotide pools, increased capability of repair
of damaged DNA, and decreased expression of human equilibrative
nucleoside transporter 1 (hENT1) involved in the transport of araC
Figure 5. ERK activation is responsible for increased NKG2D ligand expression. (A) ERK activation was assessed by Western blot anal-
ysis of constitutively active ERK (caERK)-transfected H9. Empty vector–transfected H9 cells were used as control. (B) Flow cytometric
analysis for the expression of NKG2D ligands after transfection of H9 cells with caERK. Results are representative of three different
experiments. Error bars indicate ±SD, *P < .05 compared with parental H9 cells (C) NK cell cytotoxicity experiments were performed
after transfection of H9 cells with caERK. Results are representative of three different experiments. Error bars indicate ±SD, *P < .05
compared with parental H9 cells. (D) mAb blocking experiments were performed to demonstrate the role of ULBP-2 and ULBP-3 in NK
cell lysis after transfection of H9 cells with caERK. Results are representative of three different experiments. Error bars indicate ±SD,
*P < .05 compared with cells not blocked with mAb.
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across the cell membrane, mutations of hENT1, and deoxycytidine
kinase genes have been reported [11–13,56–64]. Moreover, cell reg-
ulatory pathways such as ERK or AKTmay influence the sensitivity
of leukemic cells to araC [39–41]. Treatment of leukemic cells with
inhibitors of AKTor ERK pathways was shown to increase their sen-
sitivity to araC treatment [39–41]. Experiments performed in this
study show both AKT and ERK to be constitutively activated in
H9 cells, with increased activation of ERK but not AKT in resistant
cells relative to their parental counterparts. Treatment of leukemic
cells with pharmacological inhibitor of ERK showed no toxicity to
the cells and did not significantly influence activity of araC in resis-
tant cells. However, NKG2D ligand expression in parental and araC-
resistant leukemic cells and their corresponding lysis by NK cells
were suppressed. These findings demonstrate that ERK activation
is not a resistance mechanism in Molt-4 or H9 cells but is involved
in the sensitivity of resistant cells to NK cell lysis.
Extracellular signal–regulated kinase was also shown to increase
the expression of NKG2D ligands and the sensitivity to NK cell–
mediated lysis of transformed cells derived from solid tumors and
leukemia [42]. In fact, Borchers et al. [42] reported the involvement
of ERK signaling in the induction of surface expression of NKG2D
ligands in human tumor cells after H2O2-induced oxidative stress.
The results presented in this study demonstrate that ERK activation
is associated with increased ULBP-2 and ULBP-3 expression result-
ing in enhanced sensitivity of araC-resistant leukemic cells to NK cell
lysis. The increased ULBP-2/ULBP-3 ligand expression in constitu-
tively active ERK-transfected H9 cells and the corresponding en-
hanced NK cell lysis provide direct evidence for the involvement
of ERK activation in NKG2D ligand expression in leukemic cells.
In conclusion, this report shows for the first time that T-cell leu-
kemia cell lines that received araC treatment and became resistant are
more sensitive to NK cell attack than their parental counterparts. It is
possible that part of the efficacy of some chemotherapies and radio-
therapies, most of which activate the DNA damage response [65,66],
is due to the induction of NKG2D ligands, which, consequently, en-
hances sensitivity of the cell to the immune system. The present data
suggest that development of resistance to chemotherapeutic drugs
may be associated with increased immunogenicity of tumor cells. Be-
cause such changes persist after cessation of treatment, it is of interest
to show whether emergence of chemotherapy-resistant tumor clones
with increased sensitivity to NK cell lysis also appear in patients who
become refractory to common treatments with araC or other chemo-
therapeutic agents. The pathway leading to the up-regulation of
NKG2D ligands looks promising in the search of targets for design
of therapeutic agents to enhance the immunogenicity of transformed
cells while reducing overall toxicity.
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